Twenty-six patients with hairy cell leukemia (HCL) were treated with 2-chlorodeoxyadenosine (2-CdA), a purine analogue resistant t o adenosine deaminase, at 0.1 mg/kg/d for 7 days by continuous intravenous infusion. Fifteen patients were previously untreated, while 11 patients had received prior treatment with splenectomy alone (three patients), interferon alpha alone (four), splenectomy, then interferon alpha (two), or splenectomy, interferon alpha, then 2-deoxycoformycin (2-DCF) (two). Sixteen (80%) of 20 patients evaluable at 3 months achieved complete remission (CR), and four (20%) achieved partial remission (PR) following a single cycle of therapy. All four patients in PR had complete recovery of their peripheral blood counts (except one patient whose platelet count remained 84,OOO/pL), but had residual HCL in the bone marrow (three patients) or residual spleno- years; however, others have life-threatening pancytopenia, painful splenomegaly, or constitutional symptom^.^,^ For many years, the treatment of choice has been splenectomy, which results in normalization of peripheral blood counts in 40% to 70% of cases, but complete pathologic remissions do not occur.8-12 Interferon alpha was first reported to be effective in 1984 by Quesada et a1.13 Although interferon alpha is associated with a high response rate, the majority of responses are partial, and relapse is common when interferon is discontinued.13-17 Toxicities include flu-like symptoms, fatigue, peripheral neuropathies, and depression, as well as myelosuppression and elevated hepatic transaminases. 2-Deoxycoformycin (2-DCF, pentostatin) was the first agent to induce a significant number of complete remissions (CR) and does so in 60% to 89% of patient~.l8-~3 This agent inhibits adenosine deaminase, an enzyme involved in purine metabolism found in all lymphoid cells. Deoxyadenosine metabolites accumulate and are believed to be responsible for cytotoxicity in HCL. Toxicities include nausea, vomiting, skin rash, conjunctivitis, neurologic dysfunction, myelosuppression, and i m m u n o s u p p r e s s i~n .~~~~ 2-Chlorodeoxyadenosine (2-CdA) is a purine analogue resistant to adenosine deaminase. The drug accumulates in cells rich in deoxycytidine kinase, but low in S'-nucIeotidase activity. The triphosphate metabolite does not readily exit the cell and induces DNA double-strand breaks in both dividing and nondividing human lymphocytes.26-28 2-CdA was first reported to be effective for HCL by Piro et a1 in 1990.29 Twelve patients were treated with a single course of megaly (one). Patients with bulky adenopathy, massive splenomegaly, and severe pancytopenia responded as well as those with only modest marrow involvement. The three patients with residual marrow disease received a second cycle of 2-CdA, and two have attained CR. Therefore, 18 of 20 (90%) achieved CR with either one or two cycles of therapy. No patient achieving CR has relapsed at a median follow-up of 12 (k2.1) months. Toxicities included myelosuppression and culture-negative fever. A community-acquired pneumonia was the only infectious complication. Since a single cycle of 2-CdA induces sustained CR in the vast majority of patients with minimal toxicity, this agent is emerging as the treatment of choice for all patients with HCL.
H chronic lymphoproliferative disorder initially described by Bouroncle and Wiseman in 1958 . ' The disease is characterized by splenomegaly, pancytopenia, and infiltration of the bone marrow with lymphoid-appearing mononuclear cells that have irregular cytoplasmic projections when identified in the peripheral b l o~d .~,~ HCL is recognized as a clonal B-cell malignancy with surface antigens reflecting differentiation between the mature B cell of chronic lymphocytic leukemia and the plasma cell of m y e l~m a .~,~ Most patients have an indolent course with a median survival of 4 years; however, others have life-threatening pancytopenia, painful splenomegaly, or constitutional symptom^.^,^ For many years, the treatment of choice has been splenectomy, which results in normalization of peripheral blood counts in 40% to 70% of cases, but complete pathologic remissions do not occur. [8] [9] [10] [11] [12] Interferon alpha was first reported to be effective in 1984 by Quesada et a1. 13 Although interferon alpha is associated with a high response rate, the majority of responses are partial, and relapse is common when interferon is discontinued.13-17 Toxicities include flu-like symptoms, fatigue, peripheral neuropathies, and depression, as well as myelosuppression and elevated hepatic transaminases. 2-Deoxycoformycin (2-DCF, pentostatin) was the first agent to induce a significant number of complete remissions (CR) and does so in 60% to 89% of patient~.l8-~3 This agent inhibits adenosine deaminase, an enzyme involved in purine metabolism found in all lymphoid cells. Deoxyadenosine metabolites accumulate and are believed to be responsible for cytotoxicity in HCL. Toxicities include nausea, vomiting, skin rash, conjunctivitis, neurologic dysfunction, myelosuppression, and i m m u n o s u p p r e s s i~n .~~~~ 2-Chlorodeoxyadenosine (2-CdA) is a purine analogue resistant to adenosine deaminase. The drug accumulates in cells rich in deoxycytidine kinase, but low in S'-nucIeotidase activity. The triphosphate metabolite does not readily exit the cell and induces DNA double-strand breaks in both dividing and nondividing human lymphocytes.26-28 2-CdA was first reported to be effective for HCL by Piro et a1 in 1990.29 Twelve patients were treated with a single course of megaly (one). Patients with bulky adenopathy, massive splenomegaly, and severe pancytopenia responded as well as those with only modest marrow involvement. The three patients with residual marrow disease received a second cycle of 2-CdA, and two have attained CR. Therefore, 18 of 20 (90%) achieved CR with either one or two cycles of therapy. No patient achieving CR has relapsed at a median follow-up of 12 (k2.1) months. Toxicities included myelosuppression and culture-negative fever. A community-acquired pneumonia was the only infectious complication. Since a single cycle of 2-CdA induces sustained CR in the vast majority of patients with minimal toxicity, this agent is emerging as the treatment of choice for all patients with HCL.
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2-CdA and complete pathologic remission was achieved in 11 patients with minimal toxicity. We report the results of a phase I1 trial of 2-CdA in patients with HCL and confirm that CR is achieved in the majority of both previously treated and untreated patients.
MATERIALS AND METHODS
Between February 1991 and January 1992,26 patients with HCL were treated with 2-CdA at the Robert H. Lurie Cancer Center of Northwestern University. Eligibility criteria included the following: (1) pathologically confirmed diagnosis of HCL based on the bone marrow aspirate, core biopsy, and peripheral blood smear obtained within 2 weeks of study entry; (2) evidence of active disease, including any of the following: neutropenia (neutrophils < 1,5001 pL), anemia (hemoglobin < 12 g/dL), thrombocytopenia (platelets < 150,000/ pL), symptomatic splenomegaly, or adenopathy; (3) no active infection; (4) no prior treatment for the disease within 4 weeks of study entry; and (5) normal hepatic and renal function.
There were 22 men and four women (Table 1) . Patients ranged in age from 34 to 85 years, with a median of 47.5 years. Eleven patients had received prior treatment, while 15 were previously untreated. Prior treatment included interferon alpha alone in four patients, splenectomy alone in three patients, splenectomy then interferon alpha in two patients, and splenectomy, interferon alpha, then 2-DCF in two patients. All Patients received a single 7-day cycle and were then evaluated at 3 months. If they achieved a partial remission (PR), they were eligible to receive a second 7-day cycle. Neutropenic patients who developed fever greater than 101°F were hospitalized, cultured, and given empiric broad-spectrum antibiotics. Packed red blood cells were transfused if patients developed symptomatic anemia or a hemoglobin less than 7.0 g/dL. Platelets were given if the platelet count was less than 15,0OO/kL.
At the time of study entry, all patients had a complete history and physical examination; complete blood cell count (CBC) with differential count and platelet count; SMA-20 biochemical profile; reticulocyte count; direct and indirect Coombs test; urinalysis; electrocardiogram; chest radiograph; serum protein electrophoresis and quantitative immunoglobulins; computerized tomographic (CT) scans of the chest, abdomen, and pelvis; unilateral marrow aspirate and bone core biopsy with tartrate-resistant acid phosphatase (TRAP) and reticulin stain when necessary; and immunophenotyping and gene rearrangement studies, if a sufficient number of cells were available. During the 7 days of treatment, all patients had a daily CBC and an SMA-20 biochemical profile on days 1 and 4. Thereafter, a CBC, differential count, and platelet count were performed weekly for 8 weeks and a SMA-20 biochemical profile was obtained monthly for 3 months. Patients received daily allopurinol for 2 weeks beginning on the first day of treatment as prophylaxis against potential tumor lysis.
Bone marrow biopsies from all patients were evaluated before therapy. The median cellularity was 75% (range, 25% to 90%). Hairy cells comprised a median of 70% of the total marrow elements (range, 25% to 95%). Hairy cells were detected in the peripheral blood in all but one patient.
Initial evaluation and serial studies.

Bone marrow findings.
Response criteria. Patients were evaluable for response 3 months after the initiation of 2-CdA. All studies performed at entry were repeated. A CR required all of the following: (1) complete absence of hairy cells in the peripheral blood and bone marrow; (2) normalization of peripheral blood counts (hemoglobin 2 12 g/dL, white blood cell count 2 3,OOO/kL, neutrophils 2 1,5OO/kL, and platelet count 2 lOO,OOO/kL); (3) absence of all palpable adenopathy and hepatosplenomegaly; (4) absence of constitutional symptoms; and ( 5 ) disappearance of all abnormal adenopathy and hepatosplenomegaly by CT scans. Patients with mild residual splenomegaly ( > 12 cm, but 5 14 cm in craniocaudal dimension) or minimal soft tissue abnormality ( s 2 cm in diameter) were considered in CR.
A partial remission (PR) required all of the following: (1) reduction of greater than 50% of hairy cells in the bone marrow core biopsy; (2) increase of greater than 50% of all abnormally low peripheral blood counts; and (3) reduction of greater than 50% in abnormal adenopathy or hepatosplenomegaly.
Patients who did not fulfill the criteria for CR or PR were classified as nonresponders.
Relapse was defined as the reappearance of hairy cells in the bone marrow core biopsy after achieving a CR or an increase in greater than 50% of hairy cells in the bone marrow core biopsy after achieving a PR. Toxicity was graded according to standard criteria?O Statistical analysis. were calculated using the BMDP package, program 2D.31
Median blood counts and follow-up times
RESULTS
Accrual.
Results were analyzed as of June 1, 1992. Twenty-six consecutive patients have been treated and complete follow-up data are presented on the first 20 patients.
patients are evaluable for toxicity. Sixteen patients (80%) achieved CR and four patients (20%) achieved PR with a single cycle of 2-CdA.
The overall response rate (CR + PR) was 100%. All four patients achieving PR had marked improvement in the peripheral blood counts (Table 2) . Each patient demonstrated normalization of the absolute neutrophil count, hemoglobin, and platelet count, except one patient whose platelet count remained 84,OOO/pL. Three of the four patients achieving PR received a second course of 2-CdA because of residual HCL in the marrow. Two of these three patients achieved a CR with the second cycle and one has had no further response. The fourth patient was categorized as a PR because of residual splenomegaly measuring 16 cm. He was not retreated because his peripheral blood counts had normalized and his bone marrow was free of hairy cells. Four patients achieving CR had minimal residual splenomegaly, while one had minimal residual soft Response. tissue abnormality at sites of previous massive adenopathy. The latter patient showed continued resolution of the soft tissue abnormality at 6 months. Therefore, 18 patients (90%) achieved CR with either one or two cycles of therapy (Table 3) . No patient achieving CR has relapsed at a median follow-up (2SE) of 12 (22.1) months. One of the patients achieving PR has relapsed with recurrent thrombocytopenia and 85% hairy cells in the marrow.
The platelet count began to increase almost immediately after therapy and generally recovered by 1 month (Table 4, Fig 1) . In contrast, the absolute neutrophil count (ANC) recovered slowly, changing little during the first month. Thereafter, the ANC increased steadily and normalized by 2 months. Similarly, the improvement in the hemoglobin was delayed and paralleled that of the ANC. Eight patients required transfusion of packed red blood cells after the initiation of treatment. However, no patient required transfusion more than 2 weeks after completion of 2-CdA. Platelet transfusions were given to three patients during treatment.
The median bone marrow cellularity 3 months after treatment was 35% (range, 10% to 65%). An 85-year-old patient with pretreatment marrow cellularity of 25% achieved 65% cellularity after one cycle. The three patients achieving PR with residual disease in the marrow had an approximately 50% decrease in the percentage of hairy cells.
The most common toxicities were myelosuppression and culture-negative fever. Myelosuppression was defined as the development of a neutrophil count less than 1,000/ pL or a greater than 50% decrease from baseline, or Peripheral blood. 
Bone marrow findings.
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a platelet count less than lOO,OOO/~L, or a greater than 50% decrease from baseline. Sixteen patients (66%) developed myelosuppression with treatment; however, 10 of these 16 patients (63%) were neutropenic before therapy. Only one of these 16 patients developed thrombocytopenia. Three patients (12%) developed peripheral vein chemical phlebitis, but did not require therapy other than a change in intravenous sites. Fever greater than 101°F occurred after the initiation of 2-CdA in 12 patients (48%), most often toward the end of the 7-day cycle. In general, fever lasted 2 to 10 days; however, one patient had persistent fever for 40 days. The only confirmed infection was a community-acquired pneumonia occurring 2 weeks after treatment in a 75-year-old man whose neutrophil count was 1,350/ pL. Noninfectious hepatitis developed 2 weeks after the initiation of therapy in the patient who experienced prolonged fever. One patient developed a diffuse maculopapular skin rash 4 days after treatment, which was attributed to allopurinol. Tumor lysis syndrome did not occur. Eleven patients required admission for fever. One patient developed pain in all four extremities 4 months after receiving a second cycle of therapy. Nerve conduction velocity studies showed a mild sensory neuropathy. He died 7 months after the second cycle of a presumed cardiac event, although no autopsy was performed.
Splenic volume was estimated from CT scans by calculating the splenic index (product of the length x width x thickness) on all nonsplenectomized patients pretherapy and posttherapy. The splenic index returned to normal in only one patient posttherapy (Table 5) .
Gene rearrangement studies of peripheral blood were completed in 15 of the 20 patients before therapy (Table 6 ). Four patients showed rearrangements in both the immunoglobulin heavy chain and K light chain, and three patients in both the heavy chain and h light chain, while four patients showed rearrangements in only the heavy chain. In five patients, gene rearrangement studies were not completed due to insufficient numbers of peripheral lymphocytes. At 3 months' follow-up, two patients had persistent gene rearrangements in the peripheral blood. One such patient had circulating hairy cells and residual marrow disease (PR), while the other has remained in a CR for 13 months. However, it Splenic volume measurement.
Gene rearrangement studies.
For should be noted that posttreatment gene rearrangement studies were not completed in 14 patients due to an insufficient number of cells.
Immunophenotyping studies. Immunophenotyping studies on the peripheral blood were performed in 17 of the 20 patients before therapy (Table 6 ). Clonality was determined based on an excess of CDllc to CD15 staining, and an abnormal K to A ratio. There was evidence of an abnormal clone expressing the K light chain in seven cases and the A light chain in four cases. The remaining six cases had no abnormalities. At 3 months' follow-up, 17 patients had sufficient cells to be analyzed and immunophenotypic abnormalities persisted in three cases. Two of these patients achieved PR, while one has remained in CR for ll months.
DISCUSSION
Our results demonstrate that 2-CdA is highly effective treatment for patients with HCL. The CR rate of 90% in consecutive and nonselected patients is far superior to most other effective therapies including splenectomy, intensive chemotherapy, and interferon alpha. Every patient in our series, whether untreated or heavily pretreated, responded extremely well. Patients with bulky adenopathy and profound pancytopenia associated with replacement of the marrow responded as well as those with only modest marrow involvement. Furthermore, although follow-up is short, none of our patients achieving CR has relapsed.
Only a limited number of patients with HCL have been treated with 2-CdA.29,32-34 Our results support the observations by Piro et al, that 2-CdA induces an extremely high percentage of CRs after a single cycle of treatment with minimal t o x i~i t y .~~,~~ Estey et a1 have also recently reported CR in 36 of 46 (78%) and in a smaller study from Sweden, Juliusson and Liliemark reported CR in 12 of 16 (75%) ~atients.3~ We applied stricter criteria for CR than either of the latter two studies in that we required resolution of organomegaly by C T scan, rather than by physical examination alone.
Our study permits several new observations. First, despite resolution of splenomegaly by physical examination and conventional radiographic criteria, persistent splenomegaly was evident by measuring the splenic index, which may more accurately assess spleen ~i z e . 3~ Although the craniocaudal dimension of the spleen frequently returned to normal, the splenic index did so in only one patient, indicating that posttreatment splenomegaly may be more common than previously recognized. The single patient achieving a PR on the basis of persistent splenomegaly (16 cm) had a posttreatment splenic index less than other patients, whose spleen size was normal by craniocaudal dimension. Whether persistent splenomegaly reflects a sanctuary of residual disease is not known. Indeed, Pangalis et a1 describe six patients in whom splenectomy was performed after achieving apparent CR with interferon alpha.36 Despite resolution of splenomegaly by physical examination, persistent infiltration of the red pulp by hairy cells was present in all patients. Patients will need to be followed prospectively to determine if the posttreatment splenic index correlates with relapse. Furthermore, we suggest that a uniformly acceptable definition of CR is needed. Second, two patients relapsing after 2-DCF achieved CR with 2-CdA. Following treatment with 2-DCF, one patient's peripheral blood counts completely recovered, but residual hairy cells remained in the marrow. The second patient achieved a CR in the marrow with 2-DCF, but had a residual bulky abdominal mass. Both patients achieved a sustained CR with 2-CdA, suggesting a lack of cross-resistance between these two purine analogues. Further studies will be needed to determine if patients who fail 2-DCF will routinely respond to 2-CdA. Third, two of our patients had evidence of a persistent abnormal clone by either gene rearrangement or immunophenotyping studies after achieving a CR. Only a limited number of gene rearrangement studies in patients with HCL are available. 37 .38 The paucity of data may reflect the low number of circulating hairy cells at presentation, as well as the frequent difficulty in aspirating marrow. The importance of identifying a persistent abnormal clone by these sophisticated techniques is not known. Longer follow-up will be needed to determine whether these patients have a higher incidence of relapse. Fourth, patients achieving a PR with a single cycle may achieve a CR with a second cycle. Three patients in the present series have received a second cycle of 2-CdA because of residual HCL in the marrow (Table 2) . Two patients converted from a PR to a CR. In Piro's series, patients whose peripheral blood counts had completely recovered were not given a second cycle even if the marrow contained residual disease. More patients achieving PR will need to be treated with a second cycle of 2-CdA to permit definitive conclusions regarding efficacy. It is unclear whether patients with normal blood counts, but residual hairy cells in the marrow, benefit from further treatment. It is possible that their survival may be as lengthy as patients achieving CR. This question may never be resolved, because the CR rate with a single cycle is so high.
2-CdA appears to be more effective than interferon for HCL. A number of studies have confirmed a high overall response rate of 80% for interferon; however, the CR rate is only 5% to 40%.13J4,39340 Furthermore, clinical, as well as hematologic, improvement requires prolonged treatment. Compared with 2-CdA, recovery of peripheral counts is long (4 to 5 months), infections are common, and toxicity is significant. Although maintenance therapy may prolong remission,4l relapse is common when the treatment is s t~p p e d . l~-l~,~~ Our results appear superior to those obtained with 2-DCF in several respects. Most remarkable is the fact that results reported here were achieved with a single cycle of therapy in almost all patients, whereas remission with 2-DCF requires multiple cycles. In addition, although comparable CR rates may be achieved with both agents, toxicity is less with 2-CdA. Myelosuppression was seen in two thirds of our patients, yet only one patient developed an infection. A similar incidence of myelosuppression and infection was reported by Piro et alZ9 and Estey et al. 33 In contrast to these studies, Juliusson and Liliemark reported opportunistic infections in five of 16 patients (31%) (three fungal and two cytomegalovirus), of which two were The reason(s) for the high incidence of infection in this series is not completely clear. However, three patients were treated with either 2-DCF or interferon immediately prior to 2-CdA and as a result may have been profoundly immunosuppressed. In a study of 50 patients treated with 2-DCF, Cassileth et a1 reported a 50% incidence of infection and a 6% infectious death rate. Severe neurologic and hepatic toxicity each occurred in 4% of patients.22 In this study, 2-DCF was administered at a dose of 5 mg/m2 on 2 consecutive days every 2 weeks (40 mg/m2 every 2 months). Kraut et a1 studied a lower dose, 4 mg/m2 every other week (16 mg/m2 every 2 months), and reported less toxicity with equal efficacy. 19 In this study, although four of 23 patients (17%) had systemic infections, none were fatal. Johnston et a1 evaluated yet a lower dose of 2-DCF, 4 mg/m2/wk for 3 weeks every 8 weeks (12 mg/m2 every 2 months), and reported two episodes of septicemia, two episodes of herpes simplex, and two cases of cellulitis among 31
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From patients treated.21 Although the incidence of infection has decreased as the dose has been reduced, it is still significant. This may be attributable to the more severe immunosuppression with 2-DCF compared with 2-CdA.43 Similarly, noninfectious toxicities with 2-DCF remain substantial despite dose reduction. In Johnston's series, 76% of patients experienced nausea and vomiting, 62% lethargy, 41% skin rash, 6% altered taste, and 10% paresthesias. In contrast, the only definitive noninfectious toxicity observed with 2-CdA in the present study was fever. Since our one patient who developed a painful peripheral neuropathy received a second cycle of 2-CdA, we cannot exclude the possibility that the neuropathy represented cumulative drug toxicity. However, neurologic toxicity is extremely uncommon at this dose, and other patients in our series received a second cycle without incident.
Fludarabine is another adenosine nucleoside analogue with activity in HCL.44,45 In two brief reports, three of four patients achieved a PR. It remains to be determined whether fludarabine will have any role in the treatment of patients with HCL given the success of 2-DCF and 2-CdA.
Our data and those previously published suggest that splenectomy and interferon should no longer be considered first-line treatments for HCL, because sustained CRs rarely occur. 2-DCF may be as effective as 2-CdA, since both produce high CR rates. However, with its ease of administration and minimal toxicity, 2-CdA is emerging as the treatment of choice for all patients with HCL.
